Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07041281 · ClinicalTrials.gov registry record · Phase 2
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
A Phase 2 study of Preeclampsia and Gestational Hypertension, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 3
- Study locations
NCT07041281 is a Phase 2 study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 204 participants, below the 1,277-participant average among 39 other Preeclampsia trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT07041281, a Phase 2 study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 3
- Study locations
Study Summary
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
Conditions Studied
Interventions
- DRUG spironolactone 25 mg orally once daily
- DRUG Placebo tablet to match spironolactone
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Pennsylvania
- University of Pittsburgh Magee-Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07041281
The ClinicalTrials.gov registry entry for NCT07041281 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,277-participant average among 39 other Preeclampsia trials with a reported enrollment target (84% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which spironolactone 25 mg orally once daily is the first listed.
NCT07041281 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07041281 about?
NCT07041281 is a clinical study titled "Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories". The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension i...
What is the current status of trial NCT07041281?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2025-10-16. Estimated completion is 2029-03-02.
What conditions does trial NCT07041281 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension.
What interventions are being tested in trial NCT07041281?
The interventions under investigation include: spironolactone 25 mg orally once daily (DRUG), Placebo tablet to match spironolactone (DRUG).
Who is sponsoring clinical trial NCT07041281?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07041281 being conducted?
This trial has 3 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.